Harnessing the Power of Prostacyclins to Improve Patient Outcomes

WHO WE ARE

Experienced team dedicated to improving patient outcomes in medical conditions where there are limited or no treatment options.

OUR SCIENCE

Our focus on Prostacyclin analogues is based on research establishing PGI2 as a potent vasodilator with antiplatelet, antiproliferative and anti-inflammatory properties

PIPELINE

Our therapeutic pipeline currently focuses on a range of debilitating conditions including frostbite, systemic sclerosis and ECMO